{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:46:13Z","timestamp":1789526773534,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T00:00:00Z","timestamp":1473379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s13300-016-0197-4","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T03:44:03Z","timestamp":1473392643000},"page":"601-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Follow the LEADER\u2014Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial"],"prefix":"10.1007","volume":"7","author":[{"given":"Sanjay","family":"Kalra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,9]]},"reference":[{"issue":"5","key":"197_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.4103\/2230-8210.100629","volume":"16","author":"MP Baruah","year":"2012","unstructured":"Baruah MP, Kalra B, Kalra S. Patient centred approach in endocrinology: from introspection to action. Indian J Endocrinol Metab. 2012;16(5):679.","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"197_CR2","first-page":"5","volume":"21","author":"S Chinenye","year":"2014","unstructured":"Chinenye S, Ogbera AO, Kalra S. Patient-centered care in diabetology: Sub-Saharan African perspectives. Afr J Diabetes Med. 2014;22(1):5\u20138.","journal-title":"Afr J Diabetes Med"},{"issue":"6","key":"197_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4103\/2230-8210.102979","volume":"16","author":"S Kalra","year":"2012","unstructured":"Kalra S, Megallaa MH, Jawad F. Patient-centered care in diabetology: from eminence-based, to evidence-based, to end user-based medicine. Indian J Endocrinol Metab. 2012;16(6):871.","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"197_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ihj.2016.02.017","volume":"68","author":"M John","year":"2016","unstructured":"John M, Unnikrishnan AG, Kalra S, Nair T. Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development? Indian Heart J. 2016;68(4):564\u201371.","journal-title":"Indian Heart J"},{"issue":"14","key":"197_CR5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"3","key":"197_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"22","key":"197_CR7","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"23","key":"197_CR8","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"197_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"179","key":"197_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ahj.2016.06.004","volume":"17","author":"SP Marso","year":"2016","unstructured":"Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr P-M, Lange M, Frandsen KB, Rabol R, Buse JB. Design of DEVOTE (trial comparing cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events)\u2014DEVOTE 1. Am Heart J. 2016;17(179):175\u201383.","journal-title":"Am Heart J"},{"issue":"4","key":"197_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1479164112475102","volume":"10","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diabetes Vasc Dis Res. 2013;10(4):289\u2013301.","journal-title":"Diabetes Vasc Dis Res."},{"issue":"12","key":"197_CR12","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.2337\/dc12-0954","volume":"35","author":"O Vaccaro","year":"2012","unstructured":"Vaccaro O, Masulli M, Bonora E, Del Prato S, Nicolucci A, Rivellese AA, Riccardi G;, TOSCA.IT Study Group. The TOSCA.IT trial: a study designed to evaluate the effect of pioglitazone versus sulfonylureas on cardiovascular disease in type 2 diabetes. Diabetes Care. 2012;35(12):e82\u2013e82.","journal-title":"Diabetes Care"},{"key":"197_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4103\/2230-8210.172242","volume":"20","author":"S Kalra","year":"2016","unstructured":"Kalra S, Jacob JJ, Gupta Y. Newer antidiabetic drugs and calorie restriction mimicry. Indian J Endocr Metab. 2016;20:142\u20136.","journal-title":"Indian J Endocr Metab"},{"issue":"9131","key":"197_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study","year":"1998","unstructured":"UK Prospective Diabetes Study. UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352(9131):837\u201353.","journal-title":"Lancet."},{"key":"197_CR15","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.2337\/db14-0302","volume":"63","author":"D Beiroa","year":"2014","unstructured":"Beiroa D, Imbernon M, Gallego R, Senra A, Herranz D, Villarroya F, et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63:3346\u201358.","journal-title":"Diabetes"},{"key":"197_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.peptides.2012.10.006","volume":"39","author":"XY Miao","year":"2013","unstructured":"Miao XY, Gu ZY, Liu P, Hu Y, Li L, Gong YP, et al. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK\/mTOR\/P70S6K signaling pathway. Peptides. 2013;39:71\u20139.","journal-title":"Peptides"},{"issue":"3","key":"197_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cgh.2014.08.010","volume":"13","author":"D Festi","year":"2015","unstructured":"Festi D, Villanova N, Colecchia A. Risk factors for gallstone formation during weight loss. Clin Gastroenterol Hepatol. 2015;13(3):613.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"197_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.regpep.2012.08.005","volume":"179","author":"J Keller","year":"2012","unstructured":"Keller J, Trautmann ME, Haber H, San Tham L, Hunt T, Mace K, Linnebjerg H. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179(1):77\u201383.","journal-title":"Regul Pept"},{"issue":"2","key":"197_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/ijo.2013.83","volume":"38","author":"K Johansson","year":"2014","unstructured":"Johansson K, Sundstr\u00f6m J, Marcus C, Hemmingsson E, Neovius M. Risk of symptomatic gallstones and cholecystectomy after a very-low-calorie diet or low-calorie diet in a commercial weight loss program: 1-year matched cohort study. Int J Obes. 2014;38(2):279\u201384.","journal-title":"Int J Obes."},{"issue":"346","key":"197_CR20","doi-asserted-by":"publisher","first-page":"f2563","DOI":"10.1136\/bmj.f2563","volume":"2013","author":"LA McKenna","year":"2013","unstructured":"McKenna LA, Drummond RS, Drummond S, Talwar D, Lean ME. Seeing double: the low-carb diet. Br Med J. 2013;2013(346):f2563.","journal-title":"Br Med J"},{"key":"197_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12933-016-0431-4","volume":"15","author":"A Avogaro","year":"2016","unstructured":"Avogaro A, Fadine GP, Sesti G, Bonora E, Del Prato S. continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol. 2016;15:111.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"197_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s13300-015-0144-9","volume":"6","author":"S Kalra","year":"2015","unstructured":"Kalra S. One small step for empagliflozin, one giant leap for diabetology. Diabetes Ther. 2015;6(4):405\u20139.","journal-title":"Diabetes Ther."},{"key":"197_CR23","doi-asserted-by":"crossref","unstructured":"Kalra S, Jain A, Ved J, Unnikrishnan AG. Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect. Ind J Endocr Metab. [cited 2016 Aug 31]. http:\/\/www.ijem.in\/preprintarticle.asp?id=183826 . Accessed 31 Aug 2016 (Epub ahead of print).","DOI":"10.4103\/2230-8210.183826"},{"issue":"14","key":"197_CR24","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0002-9149(99)80683-3","volume":"75","author":"Control TD, Group CT","year":"1995","unstructured":"Control TD, Group CT. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol. 1995;75(14):894\u2013903.","journal-title":"Am J Cardiol."},{"issue":"174","key":"197_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ahj.2015.12.009","volume":"30","author":"RR Holman","year":"2016","unstructured":"Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, Khurmi NS, Mentz RJ, Oulhaj A, Buse JB, Chan JC. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J. 2016;30(174):103\u201310.","journal-title":"Am Heart J"},{"key":"197_CR26","unstructured":"Eli Lilly and Company. Researching cardiovascular events with a weekly incretin in diabetes (REWIND). clinicaltrials.gov. Bethesda: National Library of Medicine; 2011\u20132013. NLM Identifier NCT01394952."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-016-0197-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13300-016-0197-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-016-0197-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T05:02:37Z","timestamp":1568350957000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13300-016-0197-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,9]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["197"],"URL":"https:\/\/doi.org\/10.1007\/s13300-016-0197-4","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,9]]},"assertion":[{"value":"3 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}